Dirk Schadendorf, MD, Essen University Hospital

home / authors / dirk-schadendorf-md-essen-university-hospital

Articles

Dirk Schadendorf, MD

Dr. Schadendorf on Expected Toxicities With Encorafenib/Binimetinib/Pembrolizumab in BRAF V600E/K-Mutated Melanoma

Dirk Schadendorf, MD, Essen University Hospital
October 28th 2021

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Read More

Immune Checkpoint Inhibition in Stage IV Melanoma

Immune Checkpoint Inhibition in Stage IV Melanoma

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

Triple Therapy for the Management of Melanoma

Triple Therapy for the Management of Melanoma

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

COMBI-i Trial Data Updates

COMBI-i Trial Data Updates

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

Ipilimumab Dosing Significance in Adjuvant Setting

Ipilimumab Dosing Significance in Adjuvant Setting

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

KEYNOTE-054 and CheckMate 238 Trial Updates

KEYNOTE-054 and CheckMate 238 Trial Updates

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

Checkpoint Blockade Trial Data Updates

Checkpoint Blockade Trial Data Updates

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

COMBI-AD Trial 5-Year Analysis Data

COMBI-AD Trial 5-Year Analysis Data

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

Molecular Testing in Stage III Melanoma

Molecular Testing in Stage III Melanoma

Axel Hauschild, MD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, Essen University Hospital
October 12th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need